Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2600115908) titled 'Clinical Study and Novel Mechanism Exploration of Iparomlimab and Tuvonralimab Injection (QL1706) in Combination with Molecular-Targeted Therapy and Chemotherapy as First-Line Treatment for Advanced Colorectal Cancer' on Jan. 4.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Bengbu Medical University
Condition:
Colorectal cancer
Intervention:
Test group:Iparomlimab and Tuvonralimab: 5 mg/kg, IV infusion (ivgtt), every 3 weeks (Q3W)
Molecular-targeted agent(s),To be selected based on patients genetic testing results
mFOLFOX6 Regimen: Oxaliplatin, ...